9 results on '"de Kanter JK"'
Search Results
2. Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes.
- Author
-
de Kanter JK, Steemers AS, Gonzalez DM, van Ineveld RL, Blijleven C, Groenen N, Trabut L, Scheijde-Vermeulen MA, Westera L, Beishuizen A, Rios AC, Holstege FCP, Brandsma AM, Margaritis T, van Boxtel R, and Meyer-Wentrup F
- Abstract
Pediatric classic Hodgkin lymphoma (cHL) patients have a high survival rate but suffer from severe long-term side effects induced by chemo- and radiotherapy. cHL tumors are characterized by the low fraction (0.1%-10%) of malignant Hodgkin and Reed-Sternberg (HRS) cells in the tumor. The HRS cells depend on the surrounding immune cells for survival and growth. This dependence is leveraged by current treatments that target the PD-1/PD-L1 axis in cHL tumors. The development of more targeted therapies that are specific for the tumor and are therefore less toxic for healthy tissue compared with conventional chemotherapy could improve the quality of life of pediatric cHL survivors. Here, we applied single-cell RNA sequencing (scRNA-seq) on isolated HRS cells and the immune cells from the same cHL tumors. Besides TNFRSF8 (CD30), we identified other genes of cell surface proteins that are consistently overexpressed in HRS cells, such as NRXN3 and LRP8 , which can potentially be used as alternative targets for antibody-drug conjugates or CAR T cells. Finally, we identified potential interactions by which HRS cells inhibit T cells, among which are the galectin-1/CD69 and HLA-II/LAG3 interactions. RNAscope was used to validate the enrichment of CD69 and LAG3 expression on T cells near HRS cells and indicated large variability of the interaction strength with the corresponding ligands between patients and between tumor tissue regions. In conclusion, this study identifies new potential therapeutic targets for cHL and highlights the importance of studying heterogeneity when identifying therapy targets, specifically those that target tumor-immune cell interactions., Competing Interests: The authors declare no conflicts of interest., (© 2024 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematology Association.)
- Published
- 2024
- Full Text
- View/download PDF
3. Selective pressures of platinum compounds shape the evolution of therapy-related myeloid neoplasms.
- Author
-
Bertrums EJM, de Kanter JK, Derks LLM, Verheul M, Trabut L, van Roosmalen MJ, Hasle H, Antoniou E, Reinhardt D, Dworzak MN, Mühlegger N, van den Heuvel-Eibrink MM, Zwaan CM, Goemans BF, and van Boxtel R
- Subjects
- Humans, Child, Male, Female, Platinum Compounds therapeutic use, Adult, Adolescent, Whole Genome Sequencing, Phylogeny, Child, Preschool, Antineoplastic Agents therapeutic use, Single-Cell Analysis, Tumor Suppressor Protein p53 genetics, Li-Fraumeni Syndrome genetics, Germ-Line Mutation, Neoplasms, Second Primary genetics
- Abstract
Therapy-related myeloid neoplasms (t-MN) arise as a complication of chemo- and/or radiotherapy. Although t-MN can occur both in adult and childhood cancer survivors, the mechanisms driving therapy-related leukemogenesis likely vary across different ages. Chemotherapy is thought to induce driver mutations in children, whereas in adults pre-existing mutant clones are selected by the exposure. However, selective pressures induced by chemotherapy early in life are less well studied. Here, we use single-cell whole genome sequencing and phylogenetic inference to show that the founding cell of t-MN in children starts expanding after cessation of platinum exposure. In patients with Li-Fraumeni syndrome, characterized by a germline TP53 mutation, we find that the t-MN already expands during treatment, suggesting that platinum-induced growth inhibition is TP53-dependent. Our results demonstrate that germline aberrations can interact with treatment exposures in inducing t-MN, which is important for the development of more targeted, patient-specific treatment regimens and follow-up., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Sister chromatid exchanges induced by perturbed replication can form independently of BRCA1, BRCA2 and RAD51.
- Author
-
Heijink AM, Stok C, Porubsky D, Manolika EM, de Kanter JK, Kok YP, Everts M, de Boer HR, Audrey A, Bakker FJ, Wierenga E, Tijsterman M, Guryev V, Spierings DCJ, Knipscheer P, van Boxtel R, Ray Chaudhuri A, Lansdorp PM, and van Vugt MATM
- Subjects
- Chromosome Fragile Sites, Homologous Recombination genetics, DNA, Sister Chromatid Exchange, Poly(ADP-ribose) Polymerase Inhibitors pharmacology
- Abstract
Sister chromatid exchanges (SCEs) are products of joint DNA molecule resolution, and are considered to form through homologous recombination (HR). Indeed, SCE induction upon irradiation requires the canonical HR factors BRCA1, BRCA2 and RAD51. In contrast, replication-blocking agents, including PARP inhibitors, induce SCEs independently of BRCA1, BRCA2 and RAD51. PARP inhibitor-induced SCEs are enriched at difficult-to-replicate genomic regions, including common fragile sites (CFSs). PARP inhibitor-induced replication lesions are transmitted into mitosis, suggesting that SCEs can originate from mitotic processing of under-replicated DNA. Proteomics analysis reveals mitotic recruitment of DNA polymerase theta (POLQ) to synthetic DNA ends. POLQ inactivation results in reduced SCE numbers and severe chromosome fragmentation upon PARP inhibition in HR-deficient cells. Accordingly, analysis of CFSs in cancer genomes reveals frequent allelic deletions, flanked by signatures of POLQ-mediated repair. Combined, we show PARP inhibition generates under-replicated DNA, which is processed into SCEs during mitosis, independently of canonical HR factors., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
5. Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms.
- Author
-
Bertrums EJM, Rosendahl Huber AKM, de Kanter JK, Brandsma AM, van Leeuwen AJCN, Verheul M, van den Heuvel-Eibrink MM, Oka R, van Roosmalen MJ, de Groot-Kruseman HA, Zwaan CM, Goemans BF, and van Boxtel R
- Subjects
- Child, Hematopoietic Stem Cells pathology, Humans, Multiple Myeloma chemically induced, Multiple Myeloma genetics, Mutation, Neoplasms complications, Neoplasms drug therapy, Neoplasms genetics, Phylogeny, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Neoplasms, Second Primary chemically induced, Neoplasms, Second Primary genetics, Neoplasms, Second Primary pathology
- Abstract
Childhood cancer survivors are confronted with various chronic health conditions like therapy-related malignancies. However, it is unclear how exposure to chemotherapy contributes to the mutation burden and clonal composition of healthy tissues early in life. Here, we studied mutation accumulation in hematopoietic stem and progenitor cells (HSPC) before and after cancer treatment of 24 children. Of these children, 19 developed therapy-related myeloid neoplasms (t-MN). Posttreatment HSPCs had an average mutation burden increase comparable to what treatment-naïve cells accumulate during 16 years of life, with excesses up to 80 years. In most children, these additional mutations were induced by clock-like processes, which are also active during healthy aging. Other patients harbored mutations that could be directly attributed to treatments like platinum-based drugs and thiopurines. Using phylogenetic inference, we demonstrate that most t-MN in children originate after the start of treatment and that leukemic clones become dominant during or directly after chemotherapy exposure., Significance: Our study shows that chemotherapy increases the mutation burden of normal blood cells in cancer survivors. Only few drugs damage the DNA directly, whereas in most patients, chemotherapy-induced mutations are caused by processes similar to those present during normal aging. This article is highlighted in the In This Issue feature, p. 1825., (©2022 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
6. Whole-genome sequencing and mutational analysis of human cord-blood derived stem and progenitor cells.
- Author
-
Rosendahl Huber A, van Leeuwen AJCN, Peci F, de Kanter JK, Bertrums EJM, and van Boxtel R
- Subjects
- DNA Damage, Genome, Humans, Whole Genome Sequencing, Fetal Blood, Hematopoietic Stem Cells
- Abstract
Mutational signatures have been identified in cancer genomes, providing information about the causes of cancer and treatment vulnerabilities. This protocol describes an assay to determine the genotoxic mechanisms underlying these signatures using cord-blood derived hematopoietic stem and progenitor cells (CB-HSPCs). CB-HSPCs have a low mutation background, enabling sensitive detection of mutations. First, CB-HSPCs are exposed in vitro , sorted, and clonally expanded. This expansion enables whole-genome sequencing to detect the mutation load and respective patterns induced during genotoxic exposure. For complete details on the use and execution of this protocol, please refer to de Kanter et al. (2021)., Competing Interests: A.R.H., A.v.L., and R.v.B. are named as inventors on a patent application filed resulting from this work., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
7. Antiviral treatment causes a unique mutational signature in cancers of transplantation recipients.
- Author
-
de Kanter JK, Peci F, Bertrums E, Rosendahl Huber A, van Leeuwen A, van Roosmalen MJ, Manders F, Verheul M, Oka R, Brandsma AM, Bierings M, Belderbos M, and van Boxtel R
- Subjects
- Antiviral Agents therapeutic use, Humans, Transplant Recipients, Antiviral Agents adverse effects, Cytomegalovirus Infections drug therapy, Hematopoietic Stem Cell Transplantation, Mutation, Neoplasms genetics
- Abstract
Genetic instability is a major concern for successful application of stem cells in regenerative medicine. However, the mutational consequences of the most applied stem cell therapy in humans, hematopoietic stem cell transplantation (HSCT), remain unknown. Here we characterized the mutation burden of hematopoietic stem and progenitor cells (HSPCs) of human HSCT recipients and their donors using whole-genome sequencing. We demonstrate that the majority of transplanted HSPCs did not display altered mutation accumulation. However, in some HSCT recipients, we identified multiple HSPCs with an increased mutation burden after transplantation. This increase could be attributed to a unique mutational signature caused by the antiviral drug ganciclovir. Using a machine learning approach, we detected this signature in cancer genomes of individuals who received HSCT or solid organ transplantation earlier in life. Antiviral treatment with nucleoside analogs can cause enhanced mutagenicity in transplant recipients, which may ultimately contribute to therapy-related carcinogenesis., Competing Interests: Declaration of interests A.R.H., A.v.L., and R.v.B. are named as inventors on a patent application filed resulting from this work., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
8. Single-cell atlas reveals meningeal leukocyte heterogeneity in the developing mouse brain.
- Author
-
Zelco A, Börjesson V, de Kanter JK, Lebrero-Fernandez C, Lauschke VM, Rocha-Ferreira E, Nilsson G, Nair S, Svedin P, Bemark M, Hagberg H, Mallard C, Holstege FCP, and Wang X
- Subjects
- Animals, Brain pathology, Female, Leukocytes, Macrophages, Mice, Pregnancy, Meninges, Microglia
- Abstract
The meninges are important for brain development and pathology. Using single-cell RNA sequencing, we have generated the first comprehensive transcriptional atlas of neonatal mouse meningeal leukocytes under normal conditions and after perinatal brain injury. We identified almost all known leukocyte subtypes and found differences between neonatal and adult border-associated macrophages, thus highlighting that neonatal border-associated macrophages are functionally immature with regards to immune responses compared with their adult counterparts. We also identified novel meningeal microglia-like cell populations that may participate in white matter development. Early after the hypoxic-ischemic insult, neutrophil numbers increased and they exhibited increased granulopoiesis, suggesting that the meninges are an important site of immune cell expansion with implications for the initiation of inflammatory cascades after neonatal brain injury. Our study provides a single-cell resolution view of the importance of meningeal leukocytes at the early stage of development in health and disease., (© 2021 Zelco et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2021
- Full Text
- View/download PDF
9. CHETAH: a selective, hierarchical cell type identification method for single-cell RNA sequencing.
- Author
-
de Kanter JK, Lijnzaad P, Candelli T, Margaritis T, and Holstege FCP
- Subjects
- Acinar Cells immunology, Acinar Cells pathology, Base Sequence, Cell Lineage immunology, Cluster Analysis, Datasets as Topic, Dendritic Cells immunology, Dendritic Cells pathology, Gene Expression Profiling, Humans, Neoplasms immunology, Neoplasms pathology, Organ Specificity, Pancreas immunology, Pancreas pathology, RNA, Messenger genetics, Software, T-Lymphocytes immunology, T-Lymphocytes pathology, Tumor Cells, Cultured, Algorithms, Cell Lineage genetics, High-Throughput Nucleotide Sequencing methods, Neoplasms genetics, RNA, Messenger analysis, Sequence Analysis, RNA statistics & numerical data, Single-Cell Analysis methods
- Abstract
Cell type identification is essential for single-cell RNA sequencing (scRNA-seq) studies, currently transforming the life sciences. CHETAH (CHaracterization of cEll Types Aided by Hierarchical classification) is an accurate cell type identification algorithm that is rapid and selective, including the possibility of intermediate or unassigned categories. Evidence for assignment is based on a classification tree of previously available scRNA-seq reference data and includes a confidence score based on the variance in gene expression per cell type. For cell types represented in the reference data, CHETAH's accuracy is as good as existing methods. Its specificity is superior when cells of an unknown type are encountered, such as malignant cells in tumor samples which it pinpoints as intermediate or unassigned. Although designed for tumor samples in particular, the use of unassigned and intermediate types is also valuable in other exploratory studies. This is exemplified in pancreas datasets where CHETAH highlights cell populations not well represented in the reference dataset, including cells with profiles that lie on a continuum between that of acinar and ductal cell types. Having the possibility of unassigned and intermediate cell types is pivotal for preventing misclassification and can yield important biological information for previously unexplored tissues., (© The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.